	Application Number				
	Filing Date				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Chris		istoph G. LEUSSLER		
	Art Unit				
	Examiner Name				
	Attorney Docket Numb	er	PHUS030445US2		

			Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4594566		1986-06-10	Maudsley	all
	2	4746866		1988-05-24 Roschmann		all
	3	4751464		1988-06-14 Bridges		all
	4	4939465		1990-07-03 Biehl, et al.		all
	5	5543711		1996-08-06	Srinivasan, et al.	all
	6	5557247		1996-09-17	Vaughn	all
	7	6029082		2000-02-22	Srinivasan, et al.	all
	8	6043658		2000-03-28	Leussier	all

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Application Number Filing Date Filing Date Filing Date Art Unit Examiner Name Attorney Codest Number PHUS030445US2

2002-10-08 Overweg, et al.

all

	10	6591128	B1	2003-0	7-08	Wu, et al.		all			
	11	6608480	B1	2003-0	8-19	Weyers all		all			
	12	6958607	B2	2005-1	0-25	Vaughan, et al.		all			
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20020165447	A1	2002-1	1-07	Boskamp, et al.		all			
	2	20030020476	A1	2003-0	1-30	Duensing		all			
	3	20030122546	A1	2003-0	7-03	Leussler		all			
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	n citatio	n information p	olease click the Adi	d buttor	n. Add		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³			Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or		or Relevant	

9 6462636

B1

Application Number Fing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Application Number Fing Date First Numed Inventor Christoph G. LEUSSLER Art Unit Examiner Name Attorney Docket Number PHUS030463US2

al

A1 2002-11-28 KPFNV

WO02/095435

wo

	2	DE10109489	DE	A1	2001-10-11	Rapid Biomedical	all	
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n Add	
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journat, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţŝ	
	1 VAUGHAN, T., et al.; Volume Cols for Highest Field MRI; 2001; IEEE Antennas and Propagation Society Inti. Symposium; Vol. 1; 378-381.							
	2	HAYES, C.E., et al.; An 1985; J. Mag. Reson.; 6		lomoger	neous Radiofreq	uency Coil for Whole-Body	NMR Imaging at 1.5T;	
If you wis	h to a	dd additional non-paten	t literature docu	ment ci	tation informati	on please click the Add	button Add	

Tack Kinz Code of USEPO Potent Documents at time USEPI_OBJY or MEPE 981.64. Tester of this that issued the document, by the two-letter code (WPO) Standard \$1.3.) "For imprintee parties for counters, the ordinates of the year of the register of the Emperior septem charged in the ordinates of the parties for parties where of the parties for the parties of the Emperior septem process the variety and the parties and the parties and the parties and the parties are set of the parties of

FYAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner Signature

Application Number Filing Date Filing Date Filing Date First Number Inventor Christoph G. LEUSSLER Art Unit Examiner Name Attorney Oochet Number I PHUS304045USZ

CERTIFICATION STATEMENT

Please see 37 Ch	-R 1.97 and 1.98 to	make the appropriate	selection(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the contraction of the

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/TML/	Date (YYYY-MM-DD)	2006-05-16
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.